Glucagon-Like Peptide-1 Use and Healthcare Resource Utilization for Depression and Anxiety Among Adults with Type 2 Diabetes: 2019 to 2023.

IF 1.4 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Duy Do, Tiffany Lee, Angela Inneh, Urvashi Patel
{"title":"Glucagon-Like Peptide-1 Use and Healthcare Resource Utilization for Depression and Anxiety Among Adults with Type 2 Diabetes: 2019 to 2023.","authors":"Duy Do, Tiffany Lee, Angela Inneh, Urvashi Patel","doi":"10.1007/s11414-025-09950-6","DOIUrl":null,"url":null,"abstract":"<p><p>Mental health disorders, including depression and anxiety, are common comorbidities in individuals with type 2 diabetes mellitus (T2DM), contributing to increased healthcare resource utilization (HCRU) and the financial burden of the disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are commonly used for T2DM management, and emerging evidence suggests they may help alleviate mental health symptoms. This study examined the association between GLP-1RA (versus DPP-4 inhibitor [DPP-4i]) initiation and mental health-related HCRU in T2DM patients. Using data from the Komodo Healthcare Map, a national database of pharmacy and medical claims, this study conducted a retrospective cohort analysis with 774,968 adults who initiated GLP-1RAs or DPP-4i between January 2019 and March 2022. Patients were followed for 12 months, and mental health-related HCRU (emergency department, inpatient, outpatient hospital, and office visits) for depression and anxiety was assessed. A difference-in-differences analysis compared HCRU before and after medication initiation, adjusting for sociodemographic and clinical variables. GLP-1RA use was associated with significant reductions in outpatient hospital visits (IRR: 0.96; 95% CI: 0.95-0.98) for depression, and office visits for depression (IRR: 0.87; 95% CI: 0.82-0.92) and anxiety (IRR: 0.85; 95% CI: 0.81-0.90) compared to DPP-4i. However, no significant changes were observed in emergency or inpatient visits. Reductions were more pronounced with semaglutide, liraglutide, and dulaglutide. These findings suggest that GLP-1RAs may help reduce depression- and anxiety-related HCRU in patients with T2DM, indicating potential benefits beyond glycemic control. Further research is needed to explore long-term outcomes and the cost-effectiveness of GLP-1RAs for managing mental health comorbidities.</p>","PeriodicalId":49040,"journal":{"name":"Journal of Behavioral Health Services & Research","volume":" ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Behavioral Health Services & Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11414-025-09950-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Mental health disorders, including depression and anxiety, are common comorbidities in individuals with type 2 diabetes mellitus (T2DM), contributing to increased healthcare resource utilization (HCRU) and the financial burden of the disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are commonly used for T2DM management, and emerging evidence suggests they may help alleviate mental health symptoms. This study examined the association between GLP-1RA (versus DPP-4 inhibitor [DPP-4i]) initiation and mental health-related HCRU in T2DM patients. Using data from the Komodo Healthcare Map, a national database of pharmacy and medical claims, this study conducted a retrospective cohort analysis with 774,968 adults who initiated GLP-1RAs or DPP-4i between January 2019 and March 2022. Patients were followed for 12 months, and mental health-related HCRU (emergency department, inpatient, outpatient hospital, and office visits) for depression and anxiety was assessed. A difference-in-differences analysis compared HCRU before and after medication initiation, adjusting for sociodemographic and clinical variables. GLP-1RA use was associated with significant reductions in outpatient hospital visits (IRR: 0.96; 95% CI: 0.95-0.98) for depression, and office visits for depression (IRR: 0.87; 95% CI: 0.82-0.92) and anxiety (IRR: 0.85; 95% CI: 0.81-0.90) compared to DPP-4i. However, no significant changes were observed in emergency or inpatient visits. Reductions were more pronounced with semaglutide, liraglutide, and dulaglutide. These findings suggest that GLP-1RAs may help reduce depression- and anxiety-related HCRU in patients with T2DM, indicating potential benefits beyond glycemic control. Further research is needed to explore long-term outcomes and the cost-effectiveness of GLP-1RAs for managing mental health comorbidities.

胰高血糖素样肽-1在成人2型糖尿病患者抑郁和焦虑中的使用和医疗资源利用:2019 - 2023
精神健康障碍,包括抑郁和焦虑,是2型糖尿病(T2DM)患者常见的合并症,导致医疗资源利用率(HCRU)的增加和该疾病的经济负担。胰高血糖素样肽-1受体激动剂(GLP-1RAs)通常用于T2DM治疗,新出现的证据表明它们可能有助于缓解精神健康症状。本研究探讨了GLP-1RA(相对于DPP-4抑制剂[DPP-4i])起始与T2DM患者精神健康相关HCRU之间的关系。该研究使用来自国家药房和医疗索赔数据库Komodo Healthcare Map的数据,对2019年1月至2022年3月期间启动GLP-1RAs或DPP-4i的774,968名成年人进行了回顾性队列分析。随访患者12个月,评估抑郁和焦虑的心理健康HCRU(急诊科、住院、门诊和办公室就诊)。在调整了社会人口学和临床变量后,对用药前后的HCRU进行了差异中差异分析。GLP-1RA的使用与门诊医院就诊的显著减少相关(IRR: 0.96;95% CI: 0.95-0.98)和办公室就诊(IRR: 0.87;95% CI: 0.82-0.92)和焦虑(IRR: 0.85;95% CI: 0.81-0.90)与DPP-4i相比。然而,在急诊或住院病人中没有观察到明显的变化。西马鲁肽、利拉鲁肽和杜拉鲁肽的降低更为明显。这些发现表明,GLP-1RAs可能有助于降低T2DM患者抑郁和焦虑相关的HCRU,表明其潜在的益处超出了血糖控制。需要进一步的研究来探索GLP-1RAs治疗精神健康合并症的长期结果和成本效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Behavioral Health Services & Research
Journal of Behavioral Health Services & Research HEALTH CARE SCIENCES & SERVICES-PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
CiteScore
3.90
自引率
5.30%
发文量
51
审稿时长
>12 weeks
期刊介绍: This journal examines the organization, financing, delivery and outcomes of behavioral health services (i.e., alcohol, drug abuse, and mental disorders), providing practical and empirical contributions to and explaining the implications for the broader behavioral health field. Each issue includes an overview of contemporary concerns and recent developments in behavioral health policy and management through research articles, policy perspectives, commentaries, brief reports, and book reviews. This journal is the official publication of the National Council for Behavioral Health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信